<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630094</url>
  </required_header>
  <id_info>
    <org_study_id>W-5222-104</org_study_id>
    <nct_id>NCT03630094</nct_id>
  </id_info>
  <brief_title>Plasma and Intrapulmonary Concentrations Study of WCK 5222</brief_title>
  <official_title>A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 5222 (Cefepime and Zidebactam) in Healthy Adult Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, multiple dose, open-label pharmacokinetic study in healthy adult male and
      female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2017</start_date>
  <completion_date type="Actual">July 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>concentrations of cefepime (FEP) and zidebactam in epithelial lining fluid (ELF)</measure>
    <time_frame>Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>concentrations of cefepime (FEP) and zidebactam in alveolar macrophage (AM)</measure>
    <time_frame>Day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse event reported</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number variation noted in 12-lead electrocardiogram</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>PHA1A</condition>
  <arm_group>
    <arm_group_label>FEP-ZID via intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FEP-ZID</intervention_name>
    <description>A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen</description>
    <arm_group_label>FEP-ZID via intravenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) greater than or equal to18.5 and less than or equal to 30 (kg
             per m2) and weight between 55.0 and 100.0 kg (both inclusive).

          -  Medical history without any major pathology as judged by the Investigator.

          -  Forced expiratory volume in 1 second (FEV1) of at least 70% of predicted value at
             screening.

        Exclusion Criteria:

          -  History or presence of significant oncologic, cardiovascular, pulmonary, hepatic,
             renal, hematological, gastrointestinal,endocrine, immunologic, dermatologic,
             neurological, or psychiatric disease.

          -  Positive alcohol breath test or urine drug screen test at screening or confinement.

          -  Current use or has used tobacco or nicotine containing products 6 month prior to
             screening.

          -  Positive testing for HIV, Hepatitis B or Hepatitis C.

          -  History or presence of alcohol or drug abuse within the 2 years prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pulmonary Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

